BR112017014861A2 - ?combinação e composição farmacêuticas, inalador de pó seco, uso de uma combinação farmacêutica, e, método para tratamento de um distúrbio pulmonar? - Google Patents

?combinação e composição farmacêuticas, inalador de pó seco, uso de uma combinação farmacêutica, e, método para tratamento de um distúrbio pulmonar?

Info

Publication number
BR112017014861A2
BR112017014861A2 BR112017014861A BR112017014861A BR112017014861A2 BR 112017014861 A2 BR112017014861 A2 BR 112017014861A2 BR 112017014861 A BR112017014861 A BR 112017014861A BR 112017014861 A BR112017014861 A BR 112017014861A BR 112017014861 A2 BR112017014861 A2 BR 112017014861A2
Authority
BR
Brazil
Prior art keywords
pharmaceutical combination
treating
composition
dry powder
powder inhaler
Prior art date
Application number
BR112017014861A
Other languages
English (en)
Inventor
John Fish Colin
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of BR112017014861A2 publication Critical patent/BR112017014861A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)

Abstract

esta invenção fornece uma combinação farmacêutica que compreende ácido bifenil-2-ilcarbâmico 1-[2-(2-cloro-4-{[(r)-2-hidroxi-2-(8-hidroxi-2-oxo-1,2-di-hidroquinolin-5-il)etilamino]metil}-5-metoxifenilcarbamoil) etil]piperidin-4-iléster, ou um sal farmaceuticamente aceitável do mesmo, e furoato de fluticasona e uso da combinação farmacêutica em terapia, como, por exemplo, no tratamento ou profilaxia de distúrbios respiratórios ou doenças, como, por exemplo, distúrbios pulmonares tais como doença pulmonar obstrutiva crônica (copd), asma e síndrome da sobreposição de asma-copd (acqs).
BR112017014861A 2015-01-12 2016-01-11 ?combinação e composição farmacêuticas, inalador de pó seco, uso de uma combinação farmacêutica, e, método para tratamento de um distúrbio pulmonar? BR112017014861A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1500447.6A GB201500447D0 (en) 2015-01-12 2015-01-12 Novel Combination Product
PCT/EP2016/050370 WO2016113216A1 (en) 2015-01-12 2016-01-11 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
BR112017014861A2 true BR112017014861A2 (pt) 2018-01-09

Family

ID=52597490

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112017014861A BR112017014861A2 (pt) 2015-01-12 2016-01-11 ?combinação e composição farmacêuticas, inalador de pó seco, uso de uma combinação farmacêutica, e, método para tratamento de um distúrbio pulmonar?

Country Status (11)

Country Link
US (1) US20180256561A1 (pt)
EP (1) EP3244876A1 (pt)
JP (1) JP2018502861A (pt)
KR (1) KR20170102899A (pt)
CN (1) CN107106516A (pt)
AU (1) AU2016208131A1 (pt)
BR (1) BR112017014861A2 (pt)
CA (1) CA2972939A1 (pt)
GB (1) GB201500447D0 (pt)
RU (1) RU2017126153A (pt)
WO (1) WO2016113216A1 (pt)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3801456A1 (en) * 2018-06-07 2021-04-14 Kindeva Drug Delivery L.P. Fluticasone and vilanterol formulation and inhaler
US20210401855A1 (en) * 2020-06-29 2021-12-30 Cai Gu Huang Pharmaceutical formulation containing combination of m3 antagonist-beta-2 agonist and inhaled corticosteroids
CN111617138A (zh) * 2020-07-07 2020-09-04 上海凯宝药业股份有限公司 痰热清在制备慢性阻塞性肺病急性加重治疗药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070020299A1 (en) * 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
GB0602778D0 (en) * 2006-02-10 2006-03-22 Glaxo Group Ltd Novel compound
WO2009142589A1 (en) * 2008-05-20 2009-11-26 Astrazeneca Ab Combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
CN101474192A (zh) * 2009-01-20 2009-07-08 崔晓廷 糠酸氟替卡松药物制剂及制备方法
WO2011120779A1 (en) * 2010-04-01 2011-10-06 Chiesi Farmaceutici S.P.A. Process for preparing carrier particles for dry powders for inhalation

Also Published As

Publication number Publication date
KR20170102899A (ko) 2017-09-12
GB201500447D0 (en) 2015-02-25
JP2018502861A (ja) 2018-02-01
EP3244876A1 (en) 2017-11-22
RU2017126153A (ru) 2019-02-14
US20180256561A1 (en) 2018-09-13
AU2016208131A1 (en) 2017-07-20
CA2972939A1 (en) 2016-07-21
WO2016113216A1 (en) 2016-07-21
CN107106516A (zh) 2017-08-29

Similar Documents

Publication Publication Date Title
MX2022004103A (es) Una formulacion de rapamicina inhalable para tratar afecciones relacionadas con la edad.
BR112014027681A2 (pt) preparações de agentes terapêuticos hidrofóbicos, métodos de fabricação e uso dos mesmos
BR112017004048A2 (pt) formulações de pó inalável de oligômeros de alginato
BR112015006571A2 (pt) composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para a profilaxia ou tratamento de asma, doença pulmonar obstrutiva crônica e distúrbios respiratórios relacionados
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112017020039A2 (pt) composição farmacêutica, kit, método, processo para preparar uma composição e solução farmacêutica
BR112015018252A2 (pt) composição farmacêutica aquosa de dose fixa estável para administração nasal para um ser humano, composição de suspensão aquosa farmacêutica de dose fixa estável para administração nasal para um ser humano, suspensão estável adequada para administração nasal a um ser humano, método para tratar rinite em um ser humano necessitando do mesmo, uso da composição farmacêutica para administração nasal, método para liberar uma composição farmacêutica e kit
BR112016003584A8 (pt) composições farmaceuticas e uso das mesmas para regressão de placa acelerada
PH12019501408A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
BR112016027043A8 (pt) combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer
PH12019501458A1 (en) Pharmaceutical dosage forms containing task-1 and task-3 channel inhibitors, and the use of same in breathing disorder therapy
PH12016501371A1 (en) Pharmaceutical compositions comprising 15-hepe and methods of treating asthma and lung disorders using same
BR112017023351A2 (pt) composições multidrogas de matriz frágil
BR112017005828A2 (pt) métodos para tratar ou prevenir uma infecção respiratória, copd e uma exacerbação de copd e para selecionar um inibidor de sinalização notch 3 e/ou notch4, usp de um inibidor de sinalização de notch 3 e/ou notch 4, inibidor de sinalização de notch 3 e/ou notch 4, e, composição farmacêutica.
BR112017014861A2 (pt) ?combinação e composição farmacêuticas, inalador de pó seco, uso de uma combinação farmacêutica, e, método para tratamento de um distúrbio pulmonar?
BR112017003731A2 (pt) composições e métodos para prevenir ou tratar doenças, condições ou processos distinguidos por proliferação anormal de fibroblasto e deposição de matriz extracelular
EP3766508A4 (en) RAW RESIN COMPOSITION FOR THE PREVENTION OR TREATMENT OF RESPIRATORY DISEASES
BR112019001134A2 (pt) uso de lactama e composição farmacêutica
MY184269A (en) Broad-spectrum anti-influenza virus therapeutic peptides
BR112018072177A2 (pt) composição farmacêutica, recipiente, e, métodos para tratar e prevenir congestão nasal, infecções virais do trato respiratório e/ou inflamação da garganta
WO2013153349A3 (en) Pharmaceutical composition comprising arformoterol and fluticasone furoate
WO2013181217A3 (en) Novel compounds and compositions for treatment of breathing control disorders or diseases
HUE065421T2 (hu) Nazális adagolású rifampicint tartalmazó gyógyszerészeti készítmény demencia kezelésére
TR201712424A2 (tr) Kuru toz i̇nhalasyon bi̇leşi̇mleri̇
EP3295947A4 (en) PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE CONTAINING, AS AN ACTIVE INGREDIENT, AN EXTRACT, FRACTION OR ACTIVE FRACTION DEFLOS MAGNOLIAE

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired